Oncoinvent 1H26 operating loss widens to NOK 68.99 million; revenue falls to NOK 8.2 million

Reuters2026/08/27 05:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Oncoinvent posted a 1H 2026 operating loss of NOK 68.99 million, widening from NOK 52.02 million a year earlier.
Revenue fell to NOK 8.2 million from NOK 11.96 million in 1H 2025.
Cash stood at NOK 108.84 million.
Reached 50% recruitment in its Phase 2 ovarian cancer study of Radspherin, adding four new clinical sites.
CEO Oystein Soug said recruitment momentum accelerated in the first half, reinforcing confidence in Radspherin’s potential in ovarian cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncoinvent ASA published the original content used to generate this news brief via Cision (Ref. ID: 202608270100BITN____UKPR__EN_20260826-BIT-2769-0) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Oncoinvent 1H26 operating loss widens to NOK 68.99 million; revenue falls to NOK 8.2 million

You may also like

Crypto prices